SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Venus Remedies bags ‘BioSpectrum Product of the Year 2012’ award

19 Mar 2012 Evaluate

Venus Remedies has received the ‘BioSpectrum Product of the Year 2012’ award for its novel research product ‘ACHNIL’ a once-a-day painkiller. The award was presented at a glittering BioSpectrum Asia Award function in Singapore on March 16, 2012.

The product, ACHNIL was chosen for this award for its uniqueness in addressing a critical health condition. This novel formulation based on NDDS (novel drug delivery system) technology is going to fill the gap of long standing demand for better pain management therapy. ACHNIL starts its action instantly by giving immediate relief from acute pain and is effective for the next 24 hours as against the conventional daily dose of three injections of diclofenac given every 8 hours.

Aceclofenac (ACHNIL) is a radical innovation of Venus Medicine Research Centre which is a non steroidal anti-inflammatory drug (NSAID) and is used to relieve acute as well as chronic inflammation in rheumatoid arthritis. Osteoarthritis, low back pain, ankylosing spondylitis pain, dental pain post traumatic pain, gynecological pain and oncology pain. Venus has already secured patents for ACHNIL from India and Europe, which are valid up to 2025. Now, the company is all set to further strengthen its market position in India and the major European economies Germany, UK, France, Spain, Sweden, Italy and Switzerland.

Besides this, the company is also working on Antimicrobial Resistance, which is emerging as a biggest threat to the mankind. It is one of the very few R&D-led in the world working on AMR.

BioSpectrum Asia, the leading publication on Life Sciences in Asia-Pacific, which has started this award function in the year 2009 as an effort to identify and recognize the companies that are contributing to the industry's growth.

Venus Remedies Share Price

1042.35 3.25 (0.31%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×